Brief: Acadia Pharmaceuticals Q2 EPS USD 0.2 Vs. IBES Estimate USD 0.18
06/08/2024 21:05
Aug 06 (Reuters) - Acadia Pharmaceuticals Q2 product sales USD 241.963 million vs. IBES estimate USD 235.4 million. * Q2 pretax profit USD 37.182 million vs. IBES estimate USD 32.1 million * Q2 net income USD 33.389 million vs. IBES estimate USD 31.1 million * Q2 operating expenses USD 211.526 million
Recent news on Acadia Pharmaceuticals
See all newsU.S. STOCKS ON THE MOVE-FactSet, Moderna, Goldman Sachs
U.S. STOCKS ON THE MOVE-Biogen, Incyte, Quantum Cyber
U.S. STOCKS ON THE MOVE-Fortrea, Nuvation Bio, Acadia Pharmaceuticals
Acadia Pharma jumps after EU panel reverses opinion on neurological disorder drug
Brief: Daybu® (Trofinetide) Recommended For Approval In The European Union By CHMP